esketamine + pregabalin + venlafaxine

esketamine + pregabalin + venlafaxine is a combination therapy being evaluated by Beijing Tiantan Hospital for the treatment of fibromyalgia. This multi-modal approach combines esketamine, an NMDA receptor antagonist known for its rapid-acting analgesic and antidepressant properties, with pregabalin, an alpha-2-delta ligand that modulates voltage-gated calcium channels to treat neuropathic pain, and venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI). The regimen involves a single intravenous infusion of esketamine alongside a dose-escalated oral regimen of pregabalin and venlafaxine. The study aims to determine if the addition of esketamine provides superior pain relief and faster onset of action compared to the standard dual therapy of pregabalin and venlafaxine in patients with fibromyalgia, where current medications often have limited efficacy and a slow onset of action.

Other names

Esketamine plus pregabalin and venlafaxine concomitant therapy